May 19, 2017 08:34 AM EDT
R&D
Pharma

The EMA re­jects XBiotech’s can­cer drug af­ter an em­bar­rass­ing PhI­II — but they’re not giv­ing up

Shehla Shakoor

Managing Director

You can file this sto­ry in the Not Sur­prised fold­er.

Austin-based XBiotech’s ap­pli­ca­tion to start sell­ing its lead can­cer ther­a­py has been spurned by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

A service from the Financial Times